X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PEX010 (psilocybin) reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which is investigated for the treatment of adjustment disorders.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2024
Details:
Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which is investigated for the treatment of adjustment disorders.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
The net proceeds will be used to advance the Company's recently announced Phase IIb clinical trial in Australia using PEX010, a natural psilocybin drug candidate, for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 21, 2023
Details:
The net proceeds from the non-brokered private placement will be used to advance the Company's recently announced Phase IIb clinical trial in Australia using a natural PEX010 (psilocybin) in the palliative care setting and drug development.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2023
Details:
The proceeds from will help to fund the design and conduct of Psyence’s Phase IIb clinical trial using a natural psilocybin drug candidate PEX010, in the palliative care setting.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantheon Capital
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 23, 2023
Details:
Under the partnership, iNGENū will be responsible for jointly designing Psyence’s Phase IIb clinical trial, using a natural psilocybin drug candidate PEX010, in the palliative care setting.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Ingenu
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 21, 2023
Details:
The resources are expected to provide the Combined Company with the capital to advance natural psilocybin (PEX010) into a Phase IIb clinical study to be conducted under an approved protocol in Australia
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newcourt Acquisition Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 09, 2023
Details:
The agreement grants Psyence the worldwide right to commercialize Filament’s natural psilocybin drug candidate, PEX010 (psilocybin), within the context of palliative care.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: PEX010
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Filament Health
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 15, 2022
Details:
Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Brandon Kerzner
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 14, 2022
Details:
The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis. Psilocybin reduce patients’ stress and anxiety.
Lead Product(s): Psilocybin-assisted Psychotherapy
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
